Inogen, Inc. (INGN) incurred an adjusted loss per share of 45 cents for first-quarter 2024, which was narrower than the adjusted loss per share of 63 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 76 cents per share.GAAP loss per share for the quarter was 62 cents, narrower than the year-earlier loss of 88 cents per share.Revenues in DetailInogen registered revenues of $78 million for the first quarter, up 8.1% year over year. The figure surpassed the Zacks Consensus Esti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 33-0989359 (State or other jurisdiction of i ...

Inogen (INGN) reported $78.03 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 8.1%. EPS of -$0.62 for the same period compares to -$0.63 a year ago.The reported revenue represents a surprise of +6.48% over the Zacks Consensus Estimate of $73.28 million. With the consensus EPS estimate being -$0.76, the EPS surprise was +18.42%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

GOLETA, Calif., – May 07, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2024. "We are pleased to be off to a solid start at Inogen in 2024. Looking forward, we remain focused on positioning the business for revenue growth, improving our operating discipline to drive long-term profitability, and investing in our innovation pipeline to broaden our produ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer ...

Fourth Quarter 2023 Financial Results Fourth quarter total revenue was $75.9 million, relative to $88.1 million in the fourth quarter of 2022, primarily due to a decrease in domestic business-to-business sales and direct-to-consumer sales, partially offset by higher rental revenue. Total gross margin was 37.1% in the fourth quarter of 2023 versus 33.5% in the comparative period in 2022. The increase was driven primarily by lower premiums paid for components and labor and overhead costs. Total operating expe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 301 Coromar Drive Goleta, CA 93117 (Address of principal executive offices) (Zip Code) Delaware 33-0989359 (I.R.S. Employer Identification No.) ☐ TRANSITION REPORT ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2023 was $72.2 million, a decrease of 10.2% year-over-year from Q1 2022, primarily due to lower international and direct-to-consumer sales, partially offset by increased U.S. business-to-business sales and rental revenue [35][36] - Gross margin for sales revenue was 39.2% in Q1 2023, declining 220 basis points from the same period in 2022, driven by a higher volume of units sold through the business-to-business channel [18] - The company reported a net loss of $20.3 million and an adjusted EBITDA of negative $11.8 million for Q1 2023 [43][44] Business Line Data and Key Metrics Changes - Rental revenue increased by 25.4% to $16.3 million in Q1 2023 from $13 million in Q1 2022, supported by higher Medicare reimbursement rates [36] - Domestic business-to-business revenue surged 146.7% to $12.6 million in Q1 2023 compared to $5.1 million in Q1 2022, recovering from previous supply constraints [17] - Direct-to-consumer sales decreased by 29.2% to $24.3 million in Q1 2023 from $34.4 million in Q1 2022, primarily due to lower volumes from fewer inside sales representatives [38] Market Data and Key Metrics Changes - International business-to-business sales decreased by 32.1% to $19 million in Q1 2023 from $27.9 million in Q1 2022, as last year's sales were prioritized due to the pending expiration of the EU MDD certificate [37] - Foreign exchange had a negative impact of 170 basis points on total revenue and 460 basis points on international revenues [35] Company Strategy and Development Direction - The company aims to deliver low to mid-single-digit revenue growth and return to positive adjusted EBITDA by Q4 2023, viewing this year as an inflection point for stronger growth [31][34] - The strategy includes a focus on a patient-centric channel approach to enhance adoption of Inogen's POC-based therapy, driving scale and profitability [32][33] - The company is excited about expanding beyond COPD to address additional respiratory needs, including dyspnea and congestive heart failure [15] Management's Comments on Operating Environment and Future Outlook - Management noted that the first half of 2023 would be focused on regaining productivity, particularly in the direct-to-consumer segment, with expectations for improved performance in the latter half of the year [48][54] - The company is confident in its ability to meet demand for 2023, stating that Q1 performance was not supply-constrained [65] - Management expressed optimism about the progress in the prescriber channel and the overall demand for their offerings [34][54] Other Important Information - The company continues to invest in research and development, with total spending of $5.3 million in Q1 2023, consistent with the previous year [19] - As of March 31, 2023, the company had cash, cash equivalents, and marketable securities totaling $174.6 million with no debt outstanding [21] Q&A Session Summary Question: What are the drivers behind the softer domestic B2B performance? - Management indicated that the softness was due to customers reassessing capital deployment and restructuring operating expenses, but they are encouraged by the progress being made [23][54] Question: How should analysts think about the cadence of revenue throughout the year? - Management suggested that the first half of 2023 may show different performance, with expectations for a ramp-up in the back half of the year [48][54] Question: Can you clarify if the Q1 revenue was constrained by supply? - Management confirmed that Q1 performance was not supply-constrained and emphasized the importance of executing their channel strategy [65] Question: How confident is the company in achieving mid-single-digit growth for the year? - Management expressed confidence in achieving growth, citing good progress in direct-to-consumer productivity and a solid value proposition in the B2B market [54][65] Question: What is the lead time from point of contact to closing a sale? - Management indicated that the typical lead time is around 10 to 14 days from initial contact to closing [69]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...